A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
about
Pharmacogenetics of human ABC transporter ABCC11: new insights into apocrine gland growth and metabolite secretionIsolated lung perfusion as an adjuvant treatment of colorectal cancer lung metastases: a preclinical study in a pig modelPharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveFOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerMetastatic pancreatic cancer: Is there a light at the end of the tunnel?Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancerInhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancerFixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.A novel action of human apurinic/apyrimidinic endonuclease: excision of L-configuration deoxyribonucleoside analogs from the 3' termini of DNA.Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.Toxicity of a 24-hour infusion of gemcitabine in biliary tract and pancreatic cancer: a pilot study.Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.A 21-day schedule of gemcitabine and cisplatin administration in the treatment of advanced non-small cell lung carcinoma: a phase II study[Phase II trial of improved regimen with gemcitabine in patients with advanced non-small cell lung cancer].A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumoursPhase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials.Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101).Antiproliferative and apoptotic activities of ketonucleosides and keto-C-glycosides against non-small-cell lung cancer cells with intrinsic drug resistance.Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer.Chitosan and glyceryl monooleate nanostructures containing gemcitabine: potential delivery system for pancreatic cancer treatment.Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphismA phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.INDs for PET molecular imaging probes-approach by an academic institutionGemcitabine for the treatment of advanced nonsmall cell lung cancerBreast Cancer Systemic Therapy: The Need for More Economically Sustainable Scientific Strategies in the World.The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein.Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cellsLow dose rate radiosensitization of hepatocellular carcinoma in vitro and in patientsNucleoside analogues in the treatment of haematological malignancies.Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer.Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials.Noncanonical self-assembly of highly asymmetric genetically encoded polypeptide amphiphiles into cylindrical micelles.Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.Phase II study of gemcitabine in patients with advanced pancreatic cancer.
P2860
Q21131244-4E034C71-DB18-4900-AB5A-48FB2E3C2EAAQ21133613-FC6394F7-7313-4015-AE42-33BBF9EBDFD8Q26752368-3D319411-29DC-4EA4-9715-BA43F916A1D3Q28075540-68987919-0AFB-410E-A185-95AFB9C9AC43Q28082919-3C536478-A951-4C55-9C98-4F6991A51A3DQ28534413-F72FB092-6AB3-4F45-B16F-1F6541F877C9Q29547558-26FE74E2-CE39-4412-8FC6-84229E5B65B9Q30439459-074B692B-6244-458B-8B34-AA130A6F425FQ30887008-A1943925-A7B7-4ED8-A2DE-76A60A5DF0F3Q33333673-89142185-4E7E-4013-A075-B0D930BB955AQ33341524-D1C2A238-6BA9-4CDB-BD02-DCD97619C9B2Q33379886-C4D985EA-A8F0-41D5-9A94-F5BD89B2C9F4Q33389166-1138B401-FBF3-4C18-9990-77682C06E59AQ33399148-FA9E2514-C39C-4926-BC93-08CD4FB575B0Q33399656-E7F88EF1-EBFB-4478-8881-74E7A8D39DA8Q33400984-5E82AEDA-EE2B-467B-A789-003CF517B4BCQ33401071-A1F76536-ED51-4051-8B1E-0334CF526EE7Q33402401-7607C493-AAD7-4640-BBEE-4D153FF71631Q33403798-D19D88DE-143C-4B05-AB0E-976B0C792081Q33404024-69A2672E-3498-4EE8-B904-ECBFBE42A6E3Q33407276-0998B7BB-B84E-4460-99CC-F3E0A9A41F1BQ33418849-1CF6FA00-09D2-4C21-A5C8-10630EE19480Q33428122-2BB90829-F6D1-41E3-955B-E39C59B77E31Q33692259-B506D6F7-B6A3-4D00-BC6A-12C3F853108CQ33728782-994C1C3A-31D5-4BC5-B8B3-A6D06C535391Q33773101-F96171A7-0D3E-4D84-92E5-CD3DEA5AAE2AQ33847161-9EBB454F-66C8-4CC5-8673-0BDBC4D0B63FQ33862829-28E3447E-5B29-46D7-83C0-301643EF4104Q33898974-6FC6E81C-ADF2-4BB3-83D7-0D80D419DD64Q33915997-39D2A733-FB7A-4BAE-B63D-39728ECB5449Q34095977-E88C0697-B0A7-4481-B066-DCA8448F6C82Q34123758-4AB8A62A-DD86-4E03-A1ED-11010EC8EAD8Q34328748-539CC958-C8BC-46F8-9B78-E41611B06983Q34369205-A6A367F8-8675-41E5-A4B3-21290F420C86Q34390281-4E84B9D6-DCA3-4F56-8BCF-C64C9D0C8EBAQ34425234-DE6F51F6-F143-44A8-AA74-D272E805D7F3Q34439953-CB56BB03-C673-4D26-AF0D-B5E559F36D91Q34579947-206E03E6-7C24-4E91-AC3E-4E0B0E560CC9Q34609029-41AFCF7B-D7F2-43F7-8F8B-3D6E7EB2DFC3Q34732138-336691E2-3677-45B1-89D4-9A83BD6E7E30
P2860
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
description
1991 nî lūn-bûn
@nan
1991 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի մարտին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
@ast
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
@en
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
@nl
type
label
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
@ast
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
@en
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
@nl
prefLabel
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
@ast
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
@en
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
@nl
P2093
P3181
P356
P1476
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
@en
P2093
J L Abbruzzese
P Tarassoff
R Grunewald
S Mineishi
W Satterlee
P3181
P356
10.1200/JCO.1991.9.3.491
P407
P577
1991-03-01T00:00:00Z